Patrick Campbell

An analysis of data from 5 PIONEER trials is shedding new light on the impact of oral semaglutide based on background glucose-lowering therapy.

Discussing how advances in care and therapeutic agents have impacted the management of diabetes in 2020.

Results of the VERTIS-CV trial indicate ertugliflozin could reduce heart failure hospitalizations but did not demonstrate the ability to reduce MACE compared to placebo.

Discussing an analysis of retrospective claims data to examine the incidence of herpes zoster in patients with T2DM and how it impacts their diabetes.

Lead investigator of VERTIS-CV discusses results of the phase 3 trial examining ertugliflozin's impact on cardiovascular health.

An analysis of nearly 8k veterans has found use of metformin was associated with a reduction in PTSD symptoms.

Data from a phase 2 trial presented at ADA 2020 suggests ladarixin, a CXCR1/2 inhibitor, could provide benefit to patients with type 1 diabetes.

An analysis of the DECLARE-TIMI 58 trial suggests dapagliflozin use could reduce the risk of fast decline in eGFR.

Examining the results of MEX0114, a phase 2 trial evaluating the use of ladarixin in patients with new-onset type 1 diabetes.

A leader in the field diabetic care, and endocrinology as a whole, Bruce Bode, MD, offers invaluable perspective on the impact of COVID-19 on clinical practice and major trials.

Results of a new study are diving deeper into potential mediators of the effects of canagliflozin on heart failure and CV death seen in CREDENCE.

A prespecified exploratory analysis suggests the SGLT2 inhibitor reduced the rate of new-onset diabetes by nearly a third.

Chief Medical Officer of Applied Therapeutics discusses a study presented at ADA 2020 examining use of an aldose reductase inhibitor for diabetic complications.

Results of the EXPERT study could help guide clinical decision making for GLP-1 RA-experienced patients.

Discussing a look at the current life expectancy of patients with T2DM with an assistant professor from the University of Florida’s College of Pharmacy.

Discussing the results of a phase 2 study from Diasome examining use of HDV-insulin in type 1 diabetics.

Silvio Inzucchi, MD, discusses an EMPA-REG OUTCOME analysis assessing the impact of empagliflozin in patients who experience an initial dip in eGFR.

Bruce Bode, MD, discusses the results of a proof-of-concept study examining insulin and glucagon coadministration to prevent hypoglycemia and hyperglycemia in type 1 diabetics.

Deepak Bhatt, MD, MPH, discusses the results of the latest REDUCE-IT analysis, titled REDUCE-IT DIABETES, presented at ADA 2020.

Kieran Docherty, MBChB, discusses the results of a DAPA-HF analysis he presented at ADA 2020.

Discussing the effect of canagliflozin in patients with diabetes and chronic kidney disease with Meg Jardine, MBBS, PhD.

A recent analysis is examining potential factors associated with adverse gastrointestinal events in patients using semaglutide and whether it mitigates benefit.

Discussing data from ADA 2020 with a professor of medicine at University of Texas Southwestern.

A new randomized, crossover trial is examining the impact of eating dinner too late in the evening.

Increased physical activity could reduce the risk of developing age-related cataracts by up to 10%.

An NIH-funded analysis of the Jackson Heart Study is diving deeper into the impact of smoking on African Americans.

A new study from the University of Arizona is shedding light on the psychological impact of Tai Chi in patients with cardiovascular disease.

Analysis of the Framingham Heart Study indicates the rate of ICH in older patients has been on the rise and suggests anticoagulant use could have contributed to this increase.

A new analysis examines impact of treatment adherence in more than 1.2 million patients.

Study investigators have completed what they call the most comprehensive characterization of elementary school-age concussions to date.